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Abstract
Background: The presence of normal thrombolysis in myocardial infarction (TIMI) fl ow 
grade 3 before percutaneous coronary intervention (PCI) is associated with better outcomes. 
The aim of this study was to evaluate the association of spontaneous reperfusion (SR) before 
PCI and its effect on the immediate and long-term outcomes in diabetic patients. 
Methods: A total of 1,850 patients with myocardial infarction and multivessel coronary artery 
disease undergoing primary PCI were enrolled and divided into 4 groups: (1) patients with 
diabetes mellitus (DM) and initial TIMI < 3 fl ow (n = 491), (2) patients with DM and initial 
TIMI 3 fl ow (n = 48), (3) patients without DM and with initial TIMI < 3 fl ow (n = 1,196), 
(4) patients without DM and with initial TIMI 3 fl ow (n = 115). 
Results: SR before PCI was similar in diabetic and non-diabetic patients (8.9% vs. 8.8%, 
p = 0.8). DM was not an independent predictor of either pre-procedural or post-procedural 
TIMI 3 fl ow. In-hospital mortality rate was the highest in group 1 and the lowest in group 4 
(p < 0.0001). Death rates of patients from groups 2 and 3 were similar (approximately 8.3% 
each, p = 0.9). Non-diabetic patients had a higher 1-year survival rate than diabetic patients, 
irrespective of their initial TIMI fl ow. 
Conclusions: SR is associated with a similar post-PCI improvement in epicardial blood fl ow 
both in diabetic and non-diabetic patients. SR improves in-hospital survival of diabetic pa-
tients, which is similar to the survival of non-diabetic patients without SR. The benefi cial effect 
of SR in diabetic patients disappears during 1-year follow-up. (Cardiol J 2013; 20, 4: 378–384)
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Introduction
Percutaneous coronary intervention (PCI) has 
revolutionized the management and outcomes of 
patients with ST-segment elevation myocardial 
infarction (STEMI) [1]. Primary PCI, according to 
the European Society of Cardiology (ESC) 2008 
guidelines, is the treatment of choice in patients 
with STEMI within 12 h of chest pain onset [2]. 
However, the time delay associated with trans-
portation to a hospital with a catheterization 
laboratory is a major drawback of primary PCI 
and may have an adverse effect on outcomes [3]. 
Diabetes mellitus (DM) is associated with a greater 
extent of myocardial ischemia and increased mor-
tality after STEMI [4, 5]. The presence of normal 
thromb olysis in myocardial infarction (TIMI) fl ow 
grade 3 in the infarct-related artery (IRA) before 
PCI improves left ventricular function, lowers in-
cidence of congestive heart failure, and decreases 
mortality compared to patients without initial TIMI 
fl ow grade 3 [6, 7]. Yet, its incidence and impact 
among diabetic patients are unclear. Patients with 
DM have impaired endogenous fi brinolytic activity 
[8]. Therefore, the rate of spontaneous reperfusion 
(SR) before PCI may be altered and may have an 
adverse effect on outcomes.
The aim of this study was to evaluate the asso-
ciation of DM with the rate of SR before PCI and its 
effect on the immediate and long-term outcomes. 
This is an analysis of patients with STEMI and 
multivessel coronary artery disease (CAD), who 
are in our database (unpublished data).
Methods
A total of 1,850 patients with STEMI and 
multivessel CAD undergoing primary PCI were 
enrolled and divided into 4 groups depending on 
their DM status and initial TIMI fl ow in the IRA:
 — Group 1 — patients with DM and initial TIMI 
< 3 fl ow (n = 491);
 — Group 2 — patients with DM and initial TIMI 
3 fl ow (n = 48);
 — Group 3 — patients without DM and with 
initial TIMI < 3 fl ow (n = 1,196);
 — Group 4 — patients without DM and with 
initial TIMI 3 fl ow (n = 115).
SR before PCI was defi ned as the presence 
of TIMI 3 fl ow in the IRA. Multivessel CAD was 
defi ned as the presence of at least 70% stenosis of 
at least 2 epicardial coronary arteries. DM was de-
fi ned as: (a) preexisting condition diagnosed before 
STEMI (patients on insulin, oral glucose-lowering 
drugs or on a diet), (b) newly diagnosed DM based 
on fasting plasma glucose (FPG) ≥ 7.0 mmol/L 
or 2-h plasma glucose ≥ 11.1 mmol/L during an 
oral glucose tolerance test (OGTT) [9]. To avoid 
acute hyperglycemia, FPG was taken into consi-
deration after the third day of hospital stay. For 
that reason, OGTT was performed on day 4 of 
hospital stay or later. The defi nition of STEMI was 
as follows: 1) ST-segment elevation consistent 
with MI of at least 2 mm in contiguous precordial 
leads and/or ST-segment elevation of at least 
1 mm in 2 or more limb leads or new left bundle 
branch block, and 2) positive cardiac necrosis mar-
kers (CK-MB and/or troponin). Patients received 
300 mg of acetylsalicylic acid (ASA) loading dose 
and 600 mg of clopidogrel loading dose, followed 
by 75 mg of ASA maintenance dose and 75 mg 
of clopidogrel maintenance dose [10]. Coronary 
angiography and PCI were performed using stan-
dard protocols and guidelines. A culprit lesion was 
described in the presence of an acute occlusion, 
intraluminal fi lling defects (or thrombus), ulcera-
ted plaques, dissection, or intraluminal fl aps. The 
baseline and post-procedural blood flow in the 
IRA was quantifi ed with the TIMI grading system 
[11]. Angiographic measurements were made 
using quantitative coronary angiography and the 
automated coronary analysis system (CDM 3500 
View Station, Philips Medical Systems, Leiden, 
The Netherlands). All patients received bare-metal 
stents. Successful PCI was defi ned as a post-proce-
dural residual-diameter stenosis < 30%, with TIMI 
3 fl ow in the IRA and no procedural complications.
All patients were scheduled for an elective 
1-year clinical follow-up. We clinically monitored 
the patients for cardiovascular events. The major 
adverse cardiac and cerebrovascular events in-
cluded death, rehospitalization for acute coronary 
syndromes (STEMI, non-STEMI, unstable angina), 
and stroke.
Approval for analyzing recorded data was wai-
ved by the local bioethics committee on human re-
search given the retrospective nature of the study.
Statistical analysis
Quantitative data are presented as means ± 
± standard deviations (SD) or medians with inter-
quartile ranges (lower and upper quartiles). Qua-
litative data are presented as frequencies. The 
Shapiro-Wilk test was used to determine whether 
random samples came from a normal distribution. 
The c2 test with Yates’ correction was used to 
compare categorical variables. The Kruskal-Wallis 
analysis of variance (ANOVA) test was used to 
compare continuous variables between groups. 
One-year survival was estimated with the Kaplan-
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-Meier method and compared with the log-rank 
test. All clinical variables and laboratory fi ndings 
with a p value £ 0.2 in the univariate analysis were 
entered into the multivariate logistic regression 
model using a Wald statistic backward stepwise 
selection. Multivariate logistic regression analysis 
was performed to estimate odds ratios (OR) and 
95% confi dence intervals (95% CI) to identify in-
dependent predictors of baseline and fi nal TIMI 3 
fl ow. The Cox proportional hazard survival model 
was used to assess the association between TIMI 
fl ow grade and 1-year mortality while adjusting 
for potential confounders. A value of p < 0.05 was 
considered signifi cant. 
Results
A total of 539 diabetic patients entered the 
study, of whom 48 (8.9%) had SR before PCI. Addi-
tionally, 1,311 non-diabetic patients were enrolled, 
of whom 115 (8.8%) had SR before PCI (p = 0.8). 
Baseline and clinical characteristics are presented 
in Table 1. Diabetic patients (irrespective of initial 
TIMI fl ow) were older and more frequently female. 
The time from symptoms onset was substantially 
longer in diabetic patients with no SR before PCI. 
The duration of chest pain was similar in the other 
3 groups. Angiographic parameters were similar 
(Table 2) except for the rate of fi nal TIMI 3 fl ow, 
Table 1. Patients’ baseline and clinical characteristics. 
Group 1 
(n = 491)
Group 2 
(n = 48)
Group 3 
(n = 1196)
Group 4 
(n = 115)
P
Age [years] 64.3 ± 9.6 63.9 ± 8.1 59.9 ± 10.5 57.7 ± 10.9 < 0.0001
Females 214 (43.5%) 18 (35.9%) 276 (23.1%) 23 (20.0%) < 0.0001
Systemic hypertension 363 (73.9%) 36 (62.5%) 624 (52.2%) 62 (53.9%) < 0.0001
Prior myocardial infarction 191 (30.7%) 16 (33.3%) 315 (26.3%) 33 (28.7%) 0.18
Hospital stay [days] 9.5 ± 6.0 9.7 ± 5.1 8.9 ± 5.1 9.2 ± 4.1 0.15
Time from symptom onset [h], 
median (interquartile range)
6.0 (4.0–9.0) 5.0 (3.5–6.5) 5.0 (3.0–7.0) 4.0 (2.0–5.5) < 0.0001
LVEF [%], median 
(interquartile range)
42 (35–48) 40 (35–50) 45 (40–50) 45 (39–50) 0.0001
Body mass index 26.8 ± 1.3 27.1 ± 1.5 25.4 ± 1.6 24.9 ± 2.1 0.15
Aspirin 482 (98.1%) 48 (100%) 1183 (98.9%) 114 (99.1%) 0.9
Thienopyridines 
(clopidogrel/ticlopidine)
452 (92.1%) 44 (91.7%) 1112 (91.9%) 105 (91.3%) 0.7
Bea-blockers 412 (83.9%) 39 (81.2%) 981 (82.0%) 93 (80.8%) 0.6
ACE inhibitors 383 (78.0%) 36 (75.0%) 740 (61.9%) 73 (63.4%) 0.01
Statins 402 (81.9%) 39 (81.2%) 937 (78.3%) 92 (80.0%) 0.5
In-hospital death 68 (13.8%) 4 (8.3%)* 99 (8.3%)* 1 (0.9%) < 0.0001
*p = 0.99; LVEF — left ventricular ejection fraction; ACE — angiotensin converting enzyme
Table 2. Angiographic findings.
Group 1 
(n = 491)
Group 2 
(n = 48)
Group 3 
(n = 1196)
Group 4 
(n = 115)
P
Infarct-related artery: 0.8
LAD 209 (42.5%) 20 (41.7%) 504 (42.1%) 48 (41.7%)
Cx 98 (20.0%) 9 (18.7%) 245 (20.5%) 24 (20.9%)
RCA 172 (35.0%) 18 (37.5%) 406 (33.9%) 41 (35.46%)
Other 12 (2.5%) 1 (2.1%) 41 (3.4%) 2 (1.7%)
2-vessel CAD 275 (56.0%) 28 (58.3%) 650 (54.3%) 63 (54.7%) 0.8
3-vessel CAD 216 (44.0%) 20 (41.7%) 541 (45.2%) 52 (45.3%) 0.8
Final TIMI 3 flow 407 (82.9%)* 46 (97.9%)† 1033 (86.4%)* 114 (99.1%)† < 0.0001
*p = 0.5 (group 1 vs. group 3); †p = 0.8 (group 2 vs. group 4); CAD — coronary artery disease; LAD — left anterior descending branch; 
Cx — circumflex artery; RCA — right coronary artery; TIMI — thrombolysis in myocardial infarction
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which was higher in patients with SR (irrespective 
of their diabetes status). Laboratory fi ndings are 
given in Table 3. Peak creatine phosphokinase 
was higher in diabetic and non-diabetic patients 
with initial TIMI 0–2 flow (group 1 and group 
3). In-hospital mortality rate was the highest in 
group 1 and the lowest in group 4 (p < 0.0001). 
Meanwhile, the death rates of patients from groups 
2 and 3 were similar (approximately 8.3% each, 
p = 0.9). Multivariate logistic regression revealed 
that only cardiogenic shock on admission (OR 
0.25, 95% CI 0.10–0.63, p = 0.003) and time from 
symptoms onset (OR 0.95, 95% CI 0.90–0.99, p = 0.03) 
independently decreased the chance of SR be-
fore PCI. Independent predictors of final TIMI 3 
flow are depicted in Figure 1. Cardiogenic 
shock, DM, older age, time from symptoms 
onset, ejection fraction, and final TIMI 3 flow 
independently predicted in-hospital mortality 
(Fig. 2). Non-diabetic patients had a higher 
1-year survival rate than diabetic patients, irre-
spective of their initial TIMI flow (Fig. 3). The 
Cox proportional hazard survival model showed 
that only DM, cardiogenic shock, and older age 
were independently associated with 1-year 
mortality, whereas higher ejection fraction and 
Table 3. Laboratory findings.
Group 1 
(n = 491)
Group 2 
(n = 48)
Group 3 
(n = 1196)
Group 4 
(n = 115)
P
Leucocytes [103/mm3] 14.0 ± 5.5 14.9 ± 5.1 13.8 ± 6.0 13.8 ± 6.5 0.8
Erythrocytes [106/mm3] 4.5 ± 0.6 4.6 ± 0.6 4.6 ± 0.6 4.8 ± 0.7 0.3
Hemoglobin [mmol/L] 8.7 ± 0.9 9.0 ± 0.9 9.2 ± 1.0 9.0 ± 0.7 0.7
Hematocrit [%] 41 ± 5 43 ± 5 43 ± 4 44 ± 5 0.5
Platelets [103/mm3] 218 ± 68 241 ± 73 232 ± 72 224 ± 68 0.2
Admission glucose [mmol/L] 9.0 ± 4.0 9.0 ± 3.2 8.6 ± 3.9 8.6 ± 4.0 0.3
Total cholesterol [mmol/L] 5.9 (5.0–7.1) 5.8 (5.3–6.9) 6.2 (5.5–7.5) 6.0 (5.0–7.8) 0.8
HDL cholesterol [mmol/L] 1.3 (1.1–1.7) 1.5 (1.3–1.8) 1.5 (1.3–2.0) 1.6 (1.4–2.1) 0.7
LDL cholesterol [mmol/L] 4.1 (3.1–4.6) 3.8 (3.2–4.2) 3.7 (2.8–4.7) 3.8 (3.1–4.6) 0.6
Triglycerides [mmol/L] 1.5 (0.8–2.4) 1.4 (0.9–2.3) 1.3 (1.0–2.2) 1.4 (0.7–2.1) 0.7
Serum creatinine [µmol/L] 95 (75–114) 92 (73–109) 91 (74–105) 87 (63–104) 0.4
Peak CPK [IU/L] 2321 (1251–2747) 1730 (956–2144) 2179 (947–2633) 1698 (899–2038) 0.03
CPK — creatine phosphokinase
Figure 1. Independent predictors of achieving final TIMI 3 flow.
Odds ratio and 95% confidence interval
Stent placement
Initial TIMI 3 flow
Ejection fraction
(per 5% increment)
Time from symptoms onset
(per in increment)
Age (per 10−year increment)
Cardiogenic shock
p = 0.0001
p = 0.0001
p = 0.01
p = 0.02
p = 0.02
0.1
0.52
0.82
0.97
1.21
2.30
4.65
1.0 10.0
p = 0.01
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final TIMI 3 flow decreased the risk of death in 
long-term follow-up (Fig. 4).
Discussion
The results of our study indicate that the rate 
of SR before PCI was similar in diabetic and non-
-diabetic patients (8.9% vs. 8.8%). Of note, diabetic 
patients with no SR had substantially longer time 
from symptoms onset than diabetic patients with SR 
and all non-diabetic patients. Multivariate logistic 
regression revealed that only cardiogenic shock 
and the time from symptoms onset were indepen-
dent predictors of SR before PCI. The presence of 
initial TIMI 3 fl ow was associated with successful 
PCI both in diabetic and non-diabetic patients. Our 
study documents superior outcomes in patients 
who achieve TIMI 3 fl ow before intervention. In-
-hospital mortality was the highest in diabetic pa-
tients with no SR, intermediate in diabetic patients 
with SR and non-diabetic patients with no SR, and 
the lowest in non-diabetic patients with SR. Non-
-diabetic patients, irrespective of their reperfusion 
on admission status, had a good 1-year survival rate. 
Diabetic patients (irrespective of their reperfusion 
on admission status) had a worse survival rate than 
non-diabetics. Post-procedural success (fi nal TIMI 
3 fl ow) but not SR (initial TIMI 3 fl ow) was an in-
dependent predictor of 1-year mortality.
Diabetic and non-diabetic patients with initial 
TIMI 3 fl ow also had higher procedural success 
and smaller infarct sizes (lower peak creatine 
kinase values). Despite smaller infarct size and 
lower procedural success, a greater preservation 
of left ventricular function was observed only in 
non-diabetic patients. 
Unfavorable course of STEMI in diabetic 
patients may be associated with endothelial dys-
function, promoting vasoconstriction; infl ammation 
and hypercoagulability [12–14]; increased platelet 
aggregation, leading to thrombosis [15, 16]; and 
impaired endogenous fi brinolytic activity [8, 17]. 
The rate of SR in our study was similar to that ob-
served in other studies [18–20]. Unlike other studies, 
Figure 2. Independent predictors of in-hospital death.
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Figure 3. Kaplan-Meier curves for 1-year survival.
Hazard ratio and 95% confidence interval
Diabetes mellitus
Final TIMI 3 flow
Ejection fraction
(per 5% increment)
Time from symptoms onset
(per in increment)
Age (per 10−year increase)
Cardiogenic shock p < 0.0001
p = 0.009
p = 0.03
p = 0.001
p = 0.0001
0.1
0.69
0.86
1.02
1.22
1.37
8.11
1.0 10.0
p = 0.048
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Figure 4. Independent predictors of 1-year mortality.
our reports similar frequencies of SR in diabetic 
and non-diabetic patients. The benefi t of SR before 
intervention is due to multiple factors and has been 
studied in a few reports. Gustafson et al. [21] reported 
that patients with initial TIMI 2 or 3 fl ow had lower 
mortality (1.7% vs. 4.3%, p = 0.02) and a higher 
acute ejection fraction (49.5% vs. 47.1%, p = 0.002). 
Brodie et al. [22] presented similar results. Interes-
tingly, they both observed a better ejection fraction 
in patients with patent IRA on initial angiography. 
In our study, we observed no association between 
initial TIMI fl ow and ejection fraction. However, we 
did observe that diabetic patients (irrespective of 
their SR status) had more depressed left ventricular 
contractile function. Stone et al. [6], in an analysis 
of 2,507 patients from four major PAMI trials, found 
that initial TIMI 3 fl ow was a powerful and indepen-
dent predictor of in-hospital and late survival. We 
observed a similar trend in our study; nevertheless, 
SR on admission was not independently correlated 
with in-hospital and late survival. Only fi nal TIMI 3 
fl ow was an independent predictor of better survival. 
Supporting the role of pre-procedural IRA patency, De 
Luca et al. [24] found initial TIMI fl ow to be indepen-
dently associated with 1-year mortality in high-risk 
patients (according to TIMI risk score [23]), but not 
in low-risk patients.
There is only 1 prior report on the association 
of initial TIMI fl ow and DM. Bainey et al. [25] ana-
lyzed 4,944 patients (15.5% diabetic) undergoing 
primary PCI in the APEX AMI study. They repor-
ted that patients with SR had improved post-PCI 
TIMI 3 fl ow compared to those without SR in non-
-diabetic patients (99.8% vs. 90.3%, p < 0.001) and 
in diabetic patients (98.6% vs. 84.9%, p < 0.001). 
They also observed that non-diabetic patients with 
SR showed a signifi cant improvement in 90-day 
death/shock/congestive heart failure compared 
with those without SR: 4.4% vs. 8.9% (p = 0.001). 
However, the composite outcome in diabetic pa-
tients did not reach statistical signifi cance: –10.0% 
with SR vs. 14.9% without (p = 0.270). Although 
they observed a trend towards improved 90-day 
mortality in non-diabetic patients with or without 
SR (2.2% vs. 3.6%, p = 0.1), no mortality benefi t 
was evident in diabetic patients with or without 
SR (4.3% vs. 6.1%, p = 0.79). Notably, when they 
examined outcomes according to tertiles of base-
line blood glucose, both non-diabetic and diabetic 
patients with normoglycemia showed higher SR 
rates (15.5%, 10.3%, and 7.3% for non-diabetic 
patients, p < 0.001; 17.4%, 7.2%, and 9.1% for 
diabetic patients, p = 0.132) and improved 90-day 
death/shock/congestive heart failure (5.2%, 8.3%, 
and 14% for non-diabetic patients, p < 0.001; 8.7%, 
4.2%, and 15.8% for diabetic patients, p = 0.006). 
Limitations of the study
Our study has several limitations. TIMI fl ow 
in the IRA was assessed visually by the operator 
rather than by core laboratory analysis. We did not 
perform an analysis on the association between 
baseline glucose levels and the rate of SR. Because 
we analyzed patients with multivessel CAD, we do 
Hazard ratio and 95% confidence interval
Diabetes mellitus
Final TIMI 3 flow
Ejection fraction
(per 5% increment)
Age (per 10−year increment)
Cardiogenic shock p = 0.02
p = 0.0002
p = 0.03
p = 0.0009
0.1
0.69
0.91
1.40
1.48
1.56
1.0 10.0
p = 0.03
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not know whether revascularization procedures 
during follow-up were elective (staged revascu-
larization) or repeat revascularizations; therefore, 
we intentionally omitted this information in the 
results. Finally, these are observational data from 
one institution.
Conclusions
Diabetes mellitus is not an independent pre-
dictor of either pre-procedural or post-procedural 
TIMI 3 fl ow. When SR before intervention occurs, it 
is associated with a similar post-PCI improvement 
in epicardial blood fl ow both in diabetic and non-
-diabetic patients. SR improves in-hospital survival 
of diabetic patients, which is similar to the survival 
of non-diabetic patients without SR. The benefi cial 
effect of SR in diabetic patients disappears during 
1-year follow-up. 
All authors have contributed substantially to the 
study, drafted the article, revised it and gave fi nal 
approval of the version to be published.
Confl ict of interest: none declared
References
 1. A clinical trial comparing primary coronary angioplasty with tis-
sue plasminogen activator for acute myocardial infarction. The 
Global Use of Strategies to Open Occluded Coronary Arteries in 
Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy 
Investigators. N Engl J Med, 1997; 336: 1621–1628.
 2. Van de Werf F, Bax J, Betriu A et al.; ESC Committee for Practice 
Guidelines (CPG), Management of acute myocardial infarction in 
patients presenting with persistent ST-segment elevation: the 
Task Force on the Management of ST-Segment Elevation Acute 
Myocardial Infarction of the European Society of Cardiology. Eur 
Heart J, 2008; 29: 2909–2945.
 3. Mak KH, Moliterno DJ, Granger CB et al. Infl uence of diabetes 
mellitus on clinical outcome in the thrombolytic era of acute 
myocardial infarction. GUSTO-I Investigators. Global Utilization 
of Streptokinase and Tissue Plasminogen Activator for Occluded 
Coronary Arteries. J Am Coll Cardiol, 1997; 30: 171–179.
 4. Haffner FM, Lehto S, Ronnemaa T et al. Mortality from coronary 
heart disease in subjects with type 2 diabetes and in nondiabetic 
subjects with and without prior myocardial infarction. N Engl 
J Med, 1998; 339: 229–234. 
 5. Berger PB, Ellis SG, Holmes DR Jr, et al. Relationship between 
delay in performing direct coronary angioplasty and early clinical 
outcome in patients with acute myocardial infarction: results from 
the global use of strategies to open occluded arteries in Acute Coro-
nary Syndromes (GUSTO-IIb) trial. Circulation, 1999; 100: 14–20.
 6. Stone GW, Cox D, Garcia E et al. Normal fl ow (TIMI-3) before 
mechanical reperfusion therapy is an independent determinant of 
survival in acute myocardial infarction: analysis from the primary an-
gioplasty in myocardial infarction trials Circulation, 2001; 6: 636–641.
 7. Cannon CP. Importance of TIMI 3 fl ow. Circulation, 2001; 104: 
624–626.
 8. Erem C, Hacihasanoğlu A, Celik S et al. Coagulation and fi bri-
nolysis parameters in type 2 diabetic patients with and without 
diabetic vascular complications. Med Princ Pract, 2005; 14: 
22–30.
 9. Rydén L, Standl E, Bartnik M et al. Task Force on Diabetes 
and Cardiovascular Diseases of the European Society of Car-
diology (ESC); European Association for the Study of Diabetes 
(EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular 
diseases: executive summary. The Task Force on Diabetes and 
Cardiovascular Diseases of the European Society of Cardiology 
(ESC) and of the European Association for the Study of Diabetes 
(EASD). Eur Heart J, 2007; 28: 88–136.
 10. Silber S, Albertsson P, Avilés FF et al. Task Force for Percutaneo-
us Coronary Interventions of the European Society of Cardiology. 
Guidelines for percutaneous coronary interventions. The Task 
Force for Percutaneous Coronary Interventions of the European 
Society of Cardiology. Eur Heart J, 2005; 26: 804–847.
 11. TIMI Study Group Defi nitions used in TIMI trials: http://www.
timi.org. Accessed January 22, 2008.
 12. Calles-Escandon J, Cipolla M. Diabetes and endothelial dysfun-
ction: a clinical perspective. Endocr Rev, 2001; 22: 787–790.
 13. Hsueh WA, Lyon CJ, Quiñones MJ. Insulin resistance and the 
endothelium. Am J Med, 2004; 117: 109–117.
 14. Aronson D, Rayfi eld EJ, Chesebro JH. Mechanisms determining 
course and outcome of diabetic patients who have had acute my-
ocardial infarction. Ann Intern Med, 1997; 126: 296–306.
 15. Winocour PD. Platelet abnormalities in diabetes mellitus. Diabe-
tes, 1992; 41 (suppl. 2): 26–31.
 16. Davì G, Catalano I, Averna M et al. Thromboxane biosynthesis 
and platelet function in type II diabetes mellitus. N Engl J Med, 
1990; 322: 1769–1774.
 17. Nordt TK, Bode C. Impaired endogenous fi brinolysis in diabe-
tes mellitus: mechanisms and therapeutic approaches. Semin 
Thromb Hemost, 2000; 26: 495–501.
 18. Cannon CP, Gibson CM, Lambrew CT et al. Relationship of 
symptom onset-to-balloon time and door-to-balloon time with 
mortality in patients undergoing angioplasty for acute myocardial 
infarction. JAMA, 2000; 283: 2941–2947.
 19. Grines CL, Browne KF, Marco J et al. A comparison of immediate 
angioplasty with thrombolytic therapy for acute myocardial in-
farction. N Engl J Med, 1993; 328: 673–679.
 20. Stone GW, Grines CL, Browne KF et al. Predictors of in-hospital 
and 6 month outcome after acute myocardial infarction in the 
reperfusion era: the Primary Angioplasty in Myocardial Infarction 
(PAMI) trial. J Am Coll Cardiol, 1995; 25: 370–377.
 21. Gustafson JG, Cox D, Garcia E et al. Spontaneous patency in the 
early hours of AMI: incidence, predictors and prognostic implica-
tions (abstract). Circulation, 1998; 98 (suppl. I): I1–I22.
 22. Brodie BR, Stuckey TD, Hansen C et al. Benefi t of coronary 
reperfusion before intervention on outcomes after primary an-
gioplasty for acute myocardial infarction. Am J Cardiol, 2000; 85: 
13–18.
 23. Morrow DA, Antman EM, Charlesworth A et al. TIMI risk score 
for ST-elevation myocardial infarction: a convenient, bedside, cli-
nical score for risk assessment at presentation — an intravenous 
nPA for treatment of infarcting myocardium early II trial substudy. 
Circulation, 2000;102: 2031–2037.
 24. De Luca G, Ernst N, Zijlstra F, van’t Hof AW et al. Preprocedural 
TIMI fl ow and mortality in patients with acute myocardial in-
farction treated by primary angioplasty. J Am Coll Cardiol, 2004; 
43: 1363–1367.
 25. Bainey KR, Fu Y, Granger CB et al. APEX AMI Investigators. 
Benefi t of angiographic spontaneous reperfusion in STEMI: 
does it extend to diabetic patients? Heart, 2009; 95: 1331–
–1336.
